CancerIQ vs Evagene: a clinical hereditary-cancer platform vs a research and education pedigree tool

Short version. CancerIQ and Evagene are not really competitors on the same axis. CancerIQ is a clinical hereditary-cancer operations platform: it markets a short patient survey that flags patients who meet NCCN testing guidelines, auto-builds pedigrees, supports test ordering and consult letters, integrates deeply with the EHR, and reports throughput analytics for a health system running a cancer-genetics service at scale. Evagene is an academic, research, and educational pedigree-modelling platform — not a medical device, not clinical decision support, and not a clinical workflow tool. Evagene gives researchers, educators, and students a fast pedigree canvas, 20 published risk-model algorithms for illustrative and educational exploration, a CanRisk/BOADICEA export bridge, broad reference catalogues, and unusually open AI and agent surfaces (an MCP server, a Custom GPT, a REST API, and an educational correlation graph). If you are choosing between them, you are almost certainly choosing between two different jobs, not two implementations of the same job.

This article is an honest, fact-by-fact comparison. Where CancerIQ is stronger, we say so plainly — and for the clinical-workflow, EHR-integration, and test-ordering rows, CancerIQ is the right tool and Evagene deliberately does not compete. All product claims about CancerIQ are drawn from CancerIQ's public website and marketplace listings as of June 2026; if anything has since changed, CancerIQ's current pages supersede this article.

How the two products position themselves

CancerIQ, Inc. positions itself as an EHR-integrated hereditary-cancer risk platform for health systems. Its public material describes a short patient survey that flags patients who meet NCCN testing guidelines, pedigrees auto-built in line with NSGC guidelines, support for test ordering, and generation of consult notes and letters. It emphasises deep EHR integration (Epic and others), lab-order integration, and analytics and throughput reporting for a cancer-genetics service. CancerIQ is listed on the Oracle/Cerner code marketplace and on AVIA, and has been actively funded and shipping (growth capital raised in 2024). In short, it is a clinical operations platform aimed at identifying and moving patients through a hereditary-cancer pathway efficiently.

Evagene positions itself, deliberately and explicitly, as something else: an academic, research, and educational pedigree-modelling platform. It supports structured family-history documentation, teaching, and exploratory use of published risk models. Evagene is not intended to diagnose, prevent, monitor, predict, treat, or manage disease; to determine eligibility for screening, testing, referral, or treatment; or to replace professional clinical judgement. Its outputs are illustrative and for educational and research purposes only. The emphasis is on the pedigree as a teaching and research artefact, on the breadth of published models and reference data available for exploration, and on open programmatic and AI surfaces that let a pedigree be used inside research tooling and AI workspaces.

The headline difference is one of intended purpose. CancerIQ is built to run a clinical hereditary-cancer service — patient identification against guidelines, ordering, EHR-embedded workflow, and throughput. Evagene is built for learning, teaching, and research, with modern AI and API surfaces, and it does not enter the clinical care pathway at all.

Feature-by-feature comparison

The matrix below summarises the capabilities each vendor publishes on their public site, documentation, and marketplace listings. A tick means the capability is publicly advertised or documented; a dash means it is not publicly listed (which does not necessarily mean it is absent — enterprise products often keep capabilities behind sales). Where a row reflects a clinical-workflow capability, note that Evagene's dash is by design: Evagene is a research and education tool and does not implement clinical patient identification, ordering, or EHR-embedded decision support. CancerIQ wins those rows, and that is the expected and correct outcome.

Matrix compiled from publicly available product pages, marketplace listings, and marketing material as of June 2026. "—" indicates the capability is not publicly advertised and does not necessarily mean it is absent. Rows where Evagene shows a dash for a clinical-workflow capability reflect a deliberate scope boundary: Evagene is a research and education tool, not a medical device.

Clinical workflow and patient identification — CancerIQ's territory

This is the area where the two products are furthest apart, and where CancerIQ is the right answer. CancerIQ markets a short patient survey that flags patients who meet NCCN testing guidelines, then auto-builds a pedigree, supports test ordering, and generates consult notes and letters — all inside an EHR-integrated workflow with analytics on top. For a health system running a cancer-genetics service at volume, that combination of guideline-based patient identification, EHR and lab integration, and throughput reporting is exactly the operational capability the service needs, and it is purpose-built for it.

Evagene does none of this, by design. It does not flag patients against guidelines, does not order tests, does not generate clinical letters, and does not embed in an EHR as decision support. Evagene is an academic, research, and educational platform: its purpose is teaching, structured family-history documentation, and exploratory use of published models. Where CancerIQ markets clinical patient identification, test ordering, and EHR-embedded workflow, Evagene deliberately does not replicate those functions. If your need is clinical operations, CancerIQ is the platform to evaluate — not Evagene.

Risk models

CancerIQ frames its risk work around clinical guideline criteria (NCCN and similar) and does not publicly enumerate its full underlying model set. Evagene takes a different approach suited to teaching and research: it exposes 20 published risk-model algorithms as illustrative, educational tools. These include the BayesMendel suite (BRCAPRO for breast and ovarian cancer, MMRpro for Lynch syndrome, PancPRO for pancreatic cancer), Mendelian inheritance analysis for autosomal dominant, autosomal recessive, and X-linked recessive conditions, and a range of cancer family-history scoring criteria — Claus 1994, Couch 1997, Frank 2002, Manchester (Evans 2004), NICE, Amsterdam II (Vasen 1999), Bethesda (Umar 2004), and Gail 1989. See our Mendelian inheritance calculator guide for the underlying approach.

Two caveats are essential and apply to every mention of these models. First, Evagene's Tyrer-Cuzick implementation is an IBIS-style approximation of the published Tyrer/Duffy/Cuzick 2004 algorithm — it is not the official IBIS Breast Cancer Risk Evaluator binary, whose full coefficients are not public. Second, BOADICEA is not bundled. It is licensed by the University of Cambridge; Evagene exports a ##CanRisk 2.0 pedigree file that a clinician chooses to upload at canrisk.org for the clinical-grade computation off-platform. That architectural separation is intentional: Evagene's own outputs are illustrative and for educational and research purposes only, and the CanRisk bridge routes clinical-grade computation to the dedicated, properly governed tool rather than reproducing it in-app.

Because these models are framed for education and research, they are not patient triage and not clinical recommendations. They let a learner or researcher see how a published criterion or Bayesian model behaves on a worked, anonymised family — which is a different purpose from CancerIQ's guideline-driven clinical patient identification.

AI, agents, and open surfaces — Evagene's territory

Where CancerIQ is built for clinical operations, Evagene is unusually open on the AI and developer side. Its AI-assisted draft summaries help a researcher or educator produce a plain-language draft for educational or research review; the summaries are illustrative, not medical advice and not clinical recommendations. Evagene supports a bring-your-own-key (BYOK) model for Anthropic Claude and OpenAI, so AI traffic goes to the provider the user has already chosen rather than through an Evagene-hosted model.

Beyond that, Evagene ships several surfaces CancerIQ does not publicly offer. The MCP (Model Context Protocol) server exposes 15 tools to AI agents, so a researcher can read, build, or explore a pedigree from inside an MCP-compatible AI workspace. The Evagene Pedigree Builder Custom GPT lets users draft pedigrees conversationally. Related Concepts is an educational correlation graph of 1,100+ curated associations between conditions, findings, and markers — reference data for learning and exploration, never framed as risk analysis or diagnosis. And the guided Family History Questionnaire turns an intake flow into a pedigree as educational data capture; importantly, it is not a medical assessment and produces no risk output. (CancerIQ also offers a questionnaire, but its is a clinical intake feeding a clinical workflow — a different purpose from Evagene's educational capture.)

If your interest is teaching, research tooling, or building AI agents and embeds around pedigree data, these open surfaces are where Evagene is strong and where CancerIQ — a closed clinical platform — does not compete.

Interoperability and integration

CancerIQ's integration story is clinical: deep EHR integration (Epic and others), lab-order integration, and marketplace presence on Oracle/Cerner code and AVIA. That is integration into a patient-care estate, managed for a health system.

Evagene approaches interoperability through an open platform layer intended for research, teaching, and tooling rather than clinical care. A scoped, rate-limited REST API lets another system query or build pedigrees programmatically; webhooks let downstream tooling react to changes; the embeddable pedigree viewer ships as an iframe, raw SVG, or JavaScript snippet for research dashboards and teaching materials; Analysis Templates let a team codify a house style for AI-assisted educational summaries. On data portability, Evagene imports GEDCOM and 23andMe data and exports the ##CanRisk 2.0 file for the off-platform BOADICEA bridge. See our guide to GEDCOM pedigree software for why this matters for archival and multi-institution collaboration.

The distinction matters for positioning. Evagene's API is interoperability a team can choose to use; it is not an EHR-embedded clinical workflow, and Evagene does not frame it as clinical-workflow integration. The CanRisk file-export bridge is the model: a static file a clinician can choose to consume in the dedicated, governed tool off-platform.

Deployment, pricing, and governance

CancerIQ is an enterprise platform sold to health systems; pricing is not published and access is gated by sales and institutional contract. Its marketplace listings and recent funding indicate an actively shipping, growth-stage clinical product. For a large institution, that procurement model and clinical pedigree are familiar and appropriate.

Evagene is a browser-based application currently in Alpha, accessible free via a waiting list. Pricing for general availability has not been published. As a research and education platform, Evagene is not a medical device and makes no claim of regulatory clearance, device registration, or CE/UKCA/FDA marking; any compliance documentation appropriate to a given research or teaching deployment should be confirmed directly with the vendor. The same applies to CancerIQ, whose health-system customers typically request specific clinical compliance documentation as part of procurement.

When to choose CancerIQ

• You are a health system running a hereditary-cancer service and need guideline-based patient identification against NCCN criteria at scale.
• You need deep EHR integration (Epic and others) and lab-order integration inside the patient-care workflow.
• You need test ordering, consult notes, and letters generated as part of the clinical pathway.
• You want throughput and analytics reporting on your cancer-genetics service.
• You are procuring a clinical operations platform and enterprise pricing is acceptable.

When to choose Evagene

• You are teaching, learning, or researching pedigrees and want a fast drawing canvas with standard notation (ISCN/HGNC) for gesture and keyboard input.
• You want to explore how 20 published risk models behave on worked, anonymised families — for illustrative and educational purposes, not clinical decisions.
• You want a CanRisk/BOADICEA export bridge to route clinical-grade computation to the dedicated tool at canrisk.org, off-platform.
• You are building AI agents, research tooling, or embeds and want open surfaces: an MCP server, a Custom GPT, a REST API, webhooks, and an embeddable viewer.
• You want broad educational reference data — a 230+ disease catalogue, 1,900+ help guides, and a Related Concepts correlation graph.
• You want to start free today via the Alpha waiting list, and you do not need — and explicitly do not want — a clinical workflow, patient triage, or EHR-embedded decision support.

Different categories, not a head-to-head

The honest conclusion is that most teams will not choose between CancerIQ and Evagene on the same axis. If you need to identify patients against guidelines, order tests, and run a cancer-genetics service inside the EHR, CancerIQ is built for that and Evagene is not a substitute. If you need a research and education pedigree platform with published models for illustrative exploration, broad reference catalogues, and open AI and API surfaces, Evagene is built for that and a closed clinical platform is the wrong shape. The two can even be complementary: a service might run CancerIQ for clinical operations and use Evagene separately for teaching, training, or research — with the clear understanding that Evagene's outputs are educational and illustrative only, never clinical recommendations or patient triage.

Frequently asked questions

Related comparisons and reading

• Phenotips vs Evagene
• Best hereditary-cancer risk tools
• Hereditary cancer risk assessment
• Evagene for clinical geneticists
• Compare Evagene with other tools